Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There is accumulating evidence that genetic expression plays a role in autism spectrum disorder, but the regulation of such genes is poorly understood. Small RNA particles, called microRNA (miRNA), have the ability to alter gene expression. These particles can be packaged and released from brain cells into the blood. Changes in miRNA may contribute to the patterns observed in autism spectrum disorder.
The purpose of this study is to identify small RNA particles that regulate gene expression in autism spectrum disorder. The goal is to identify miRNA expression patterns which may improve our understanding and diagnosis of autism spectrum disorder.
| Condition |
|---|
|
Autism Spectrum Disorder Exosomal miRNA Expression |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
- Exosomal microRNA expression patterns [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Whole Blood
| Estimated Enrollment: | 40 |
| Study Start Date: | January 2013 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Autism
Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
|
|
Control
Age- and gender-matched controls with typical neuropsychological developmental patterns
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 4 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Children from the University Pediatric and Adolescent Center and the Center for Development Behavior and Genetics in Syracuse, New York.
Inclusion Criteria:
- Children ages 4-17
Exclusion Criteria:
- neurological impairments (i.e. cerebral palsy, epilepsy)
- sensory deficits (i.e. sensory or visual impairments)
- psychological disorders (i.e. obsessive compulsive disorder, attention deficit disorder)
- control subjects with family history of autism spectrum disorder
- mental retardation
- history of preterm birth
Contacts and Locations| Contact: Steven Hicks, MD, PhD | 845 518 0649 | hickss@upstate.edu |
| United States, New York | |
| SUNY Upstate Medical University | Not yet recruiting |
| Syracuse, New York, United States, 13210 | |
| Contact: Steven Hicks, MD, PhD 845-518-0649 hickss@upstate.edu | |
| Principal Investigator: | Steven Hicks, MD, PhD | SUNY Upstate Medical University, Department of Pediatrics |
More Information
No publications provided
| Responsible Party: | State University of New York - Upstate Medical University |
| ClinicalTrials.gov Identifier: | NCT01749670 History of Changes |
| Other Study ID Numbers: | 346301-1 |
| Study First Received: | December 12, 2012 |
| Last Updated: | December 13, 2012 |
| Health Authority: | United States: Institutional Review Board United States: Data and Safety Monitoring Board |
Keywords provided by State University of New York - Upstate Medical University:
|
Autism Spectrum Disorder Exosomal miRNA expression |
Additional relevant MeSH terms:
|
Autistic Disorder Child Development Disorders, Pervasive Mental Disorders Diagnosed in Childhood Mental Disorders |
ClinicalTrials.gov processed this record on May 19, 2013